177 related articles for article (PubMed ID: 36786635)
1. Circulating DNA methylation profile improves the accuracy of serum biomarkers for the detection of nonmetastatic hepatocellular carcinoma.
Phan TH; Chi Nguyen VT; Thi Pham TT; Nguyen VC; Ho TD; Quynh Pham TM; Tran TH; Nguyen TD; Khang Le ND; Nguyen TH; Duong ML; Bach HT; Kim VV; Pham TA; Nguyen BT; Vo Nguyen TN; Nguyen TD; Bieu Phu DT; Huu Phan BH; Nguyen DS; Truong DK; Do TT; Giang H; Nguyen HN; Phan MD; Tran LS
Future Oncol; 2022 Dec; 18(39):4399-4413. PubMed ID: 36786635
[TBL] [Abstract][Full Text] [Related]
2. Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) based on gender, age, multitarget circulating tumour DNA methylation signature and commonly used serological biomarkers for early detection of hepatocellular carcinoma: a multicentre, prospective observational study protocol.
Yang T; Wang N; Wang F; Liu H; Shen F; Lv G
BMJ Open; 2023 Sep; 13(9):e076467. PubMed ID: 37723113
[TBL] [Abstract][Full Text] [Related]
3. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
[TBL] [Abstract][Full Text] [Related]
4. Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma.
Luo B; Ma F; Liu H; Hu J; Rao L; Liu C; Jiang Y; Kuangzeng S; Lin X; Wang C; Lei Y; Si Z; Chen G; Zhou N; Liang C; Jiang F; Liu F; Dai W; Liu W; Gao Y; Li Z; Li X; Zhou G; Li B; Zhang Z; Nian W; Luo L; Liu X
BMC Med; 2022 Jan; 20(1):8. PubMed ID: 35027051
[TBL] [Abstract][Full Text] [Related]
5. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma.
Chalasani NP; Porter K; Bhattacharya A; Book AJ; Neis BM; Xiong KM; Ramasubramanian TS; Edwards DK; Chen I; Johnson S; Roberts LR; Kisiel JB; Reddy KR; Singal AG; Olson MC; Bruinsma JJ
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):173-182.e7. PubMed ID: 34391922
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.
Malik J; Klammer M; Rolny V; Chan HL; Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; Swiatek-de Lange M
World J Gastroenterol; 2022 Aug; 28(29):3917-3933. PubMed ID: 36157551
[TBL] [Abstract][Full Text] [Related]
7. Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma.
Jain S; Chen S; Chang KC; Lin YJ; Hu CT; Boldbaatar B; Hamilton JP; Lin SY; Chang TT; Chen SH; Song W; Meltzer SJ; Block TM; Su YH
PLoS One; 2012; 7(4):e35789. PubMed ID: 22536438
[TBL] [Abstract][Full Text] [Related]
8. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma.
Lu CY; Chen SY; Peng HL; Kan PY; Chang WC; Yen CJ
Oncotarget; 2017 Jan; 8(4):6406-6418. PubMed ID: 28031532
[TBL] [Abstract][Full Text] [Related]
9. A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma.
Kim SC; Kim DW; Cho EJ; Lee JY; Kim J; Kwon C; Kim-Ha J; Hong SK; Choi Y; Yi NJ; Lee KW; Suh KS; Kim W; Kim W; Kim H; Kim YJ; Yoon JH; Yu SJ; Kim YJ
Mol Cancer; 2023 Oct; 22(1):164. PubMed ID: 37803338
[TBL] [Abstract][Full Text] [Related]
10. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
Singal AG; Tayob N; Mehta A; Marrero JA; El-Serag H; Jin Q; Saenz de Viteri C; Fobar A; Parikh ND
Hepatology; 2022 Mar; 75(3):541-549. PubMed ID: 34618932
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
[TBL] [Abstract][Full Text] [Related]
12. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.
Xu F; Zhang L; He W; Song D; Ji X; Shao J
Dis Markers; 2021; 2021():8868370. PubMed ID: 33628341
[TBL] [Abstract][Full Text] [Related]
13. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma.
Chalasani NP; Ramasubramanian TS; Bhattacharya A; Olson MC; Edwards V DK; Roberts LR; Kisiel JB; Reddy KR; Lidgard GP; Johnson SC; Bruinsma JJ
Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2597-2605.e4. PubMed ID: 32889146
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study.
Lewin J; Kottwitz D; Aoyama J; deVos T; Garces J; Hasinger O; Kasielke S; Knaust F; Rathi P; Rausch S; Weiss G; Zipprich A; Mena E; Fong TL
BMC Gastroenterol; 2021 Mar; 21(1):136. PubMed ID: 33765926
[TBL] [Abstract][Full Text] [Related]
15. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
[No Abstract] [Full Text] [Related]
16. Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study.
Guo DZ; Huang A; Wang YC; Zhou S; Wang H; Xing XL; Zhang SY; Cheng JW; Xie KH; Yang QC; Ma CC; Li Q; Chen Y; Su ZX; Fan J; Liu R; Liu XL; Zhou J; Yang XR
Clin Transl Med; 2024 May; 14(5):e1652. PubMed ID: 38741204
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
18. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.
Lok AS; Sterling RK; Everhart JE; Wright EC; Hoefs JC; Di Bisceglie AM; Morgan TR; Kim HY; Lee WM; Bonkovsky HL; Dienstag JL;
Gastroenterology; 2010 Feb; 138(2):493-502. PubMed ID: 19852963
[TBL] [Abstract][Full Text] [Related]
19. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
